

03/07/02
JCS60 U.S. PTO

10091526 030702

2010/07/02
PTD
92168/107
10/07/02

Please type a plus sign (+) inside this box ☒

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 CFR 1.53(b))</small>		Attorney Docket PT229C1 First Inventor Rosen et al. Title Nucleic Acids, Proteins, and Antibodies Express Mail Label	
APPLICATION ELEMENTS <small>See MPEP chapter 600 concerning utility patent application contents</small>		ADDRESS TO: Box Patent Application Commissioner for Patents Washington, DC 20231	
1 <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <small>(Submit an original, and a duplicate for fee processing)</small> 2 <input type="checkbox"/> Applicant claims small entity status <small>See 37 CFR 1.27</small> 3 <input checked="" type="checkbox"/> Specification [Total Pages 397] <small>(preferred arrangement set forth below)</small> <ul style="list-style-type: none"> - Descriptive title of the invention - Cross Reference to Related Applications - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claims - Abstract of the Disclosure 4 <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total Sheets] 5 Oath or Declaration [Total Pages 5] <div style="margin-left: 20px;"> a <input type="checkbox"/> Newly executed (original or copy) b <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <small>(for continuator/divisional with Box 18 completed)</small> c <input type="checkbox"/> DELETION OF INVENTOR(S) <small>Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(b)(2) and 1.53(b).</small> </div> 6 <input checked="" type="checkbox"/> Application Data Sheet See 37 CFR 1.76 (7 pages)	7 <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8 <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a <input checked="" type="checkbox"/> Computer Readable Form (CRF) b Specification Sequence Listing on i <input checked="" type="checkbox"/> CD-ROM or CD-R (2 copies), or ii <input type="checkbox"/> paper c <input checked="" type="checkbox"/> Statements verifying identity of above copies		
ACCOMPANYING APPLICATIONS PARTS			
9 <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10 <input type="checkbox"/> 37 CFR 373(b) Statement <input checked="" type="checkbox"/> Associate Power of Attorney <small>(when there is an assignee)</small> 11 <input type="checkbox"/> English Translation Document (if applicable) 12 <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 13 <input type="checkbox"/> Preliminary Amendment 14 <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <small>(Should be specifically itemized)</small> 15 <input type="checkbox"/> Certified Copy of Priority Document(s) <small>(if foreign priority is claimed)</small> 16 <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i) 17 <input checked="" type="checkbox"/> Other <div style="margin-left: 20px; border: 1px solid black; padding: 2px;"> 1. Statement Under 37 C.F.R. § 1.821 2. Transmittal and Submission Under 37 C.F.R. §§ 1.824 and 1.52(e) </div>			
18 If a CONTINUING APPLICATION , check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76 <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No. 09/764,889 Prior application information: Examiner Clow, L. Group / Art Unit 1631 For CONTINUATION or DIVISIONAL APPS only The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.			
19. CORRESPONDENCE ADDRESS			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		22195 or <input type="checkbox"/> Correspondence address below	
Name _____ Address _____ City _____ State _____ Zip Code _____ Country _____ Telephone _____ Fax _____			
Name (Print/Type) Mark J. Hyman		Registration No. (Attorney/Agent) 46,789	
Signature		Date March 7, 2002	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2002

Patent fees are subject to annual revision.

☐ Application claims small entity status See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**896.00**

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Rosen et al.
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	PTZ29C1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number

08-3425

Deposit Account Name

Human Genome Sciences, Inc.

The Commissioner is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
101	740	201	370	Utility filing fee	740.00
106	330	206	165	Design filing fee	
107	510	207	255	Plant filing fee	
108	740	208	370	Reissue filing fee	
114	160	214	80	Provisional filing fee	
SUBTOTAL (1) (\$)					740.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Fee from Claim(s)		Fee Paid
Independent Claims	24	-20** = 4	x 18.00 =	72.00
Multiple Dependent	4	-3** = 1	x 84.00 =	84.00

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description
103	18	203	9	Claims in excess of 20
102	84	202	42	Independent claims in excess of 3
104	280	204	140	Multiple dependent claim, if not paid
109	84	209	42	** Reissue independent claims over original patent
110	18	210	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**156.00**

**or number previously paid, if greater. For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
105	130	205	65	Surcharge - late filing fee or oath	
127	50	227	25	Surcharge - late provisional filing fee or cover sheet	
139	130	139	130	Non-English specification	
147	2,520	147	2,520	For filing a request for ex parte reexamination	
112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
115	110	215	55	Extension for reply within first month	
116	400	216	200	Extension for reply within second month	
117	920	217	460	Extension for reply within third month	
118	1,440	218	720	Extension for reply within fourth month	
128	1,960	228	980	Extension for reply within fifth month	
119	320	219	160	Notice of Appeal	
120	320	220	160	Filing a brief in support of an appeal	
121	280	221	140	Request for oral hearing	
138	1,510	138	1,510	Petition to institute a public use proceeding	
140	110	240	55	Petition to revive - unavoidable	
141	1,280	241	640	Petition to revive - unintentional	
142	1,280	242	640	Utility issue fee (or reissue)	
143	460	243	230	Design issue fee	
144	620	244	310	Plant issue fee	
122	130	122	130	Positions to the Commissioner	
123	50	123	50	Processing fee under 37 CFR 1.17(g)	
126	180	126	180	Submission of Information Disclosure Sheet	
581	40	581	40	Recording each patent assignment per priority (times number of priorities)	
146	740	246	370	Filing a submission after final rejection (37 CFR 1.129(a))	
149	740	249	370	For each additional invention to be examined (37 CFR 1.124(b))	
179	740	279	370	Request for Continued Examination (RCE)	
169	900	169	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**0.00**

SUBMITTED BY

Name (Print/Type) **Mark J. Hyman**

Registration No (Attorney/Agent) **46,789**

Complete (if applicable)

Telephone **(240) 314-1224**

Signature



Date

March 7, 2002

VIA HAND DELIVERY MARCH 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PTZ29C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies


STATEMENT UNDER 37 C.F.R. § 1.821Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. § 1.821(f), Applicants hereby certify that the sequence listing information recorded in computer readable form and submitted herewith is identical to the written (on compact disc) Sequence Listing submitted herewith.

Respectfully submitted,

Dated: March 7, 2002

Mark J. Hyman
Attorney for Applicants

Reg. No. 46,789

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures

VIA HAND DELIVERY MARCH 7, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Rosen et al.

Attorney Docket No.: PTZ29C1

Application Serial No.: Not Yet Assigned

Art Unit: Not Yet Assigned

Filed: Herewith

Examiner: Not Yet Assigned

Title: Nucleic Acids, Proteins, and Antibodies

**TRANSMITTAL AND SUBMISSION UNDER
37 C.F.R. §§ 1.824 AND 1.52(e)**Commissioner for Patents
Washington, D.C. 20231


Sir:

In accordance with 37 C.F.R. §§ 1.821(e) and 1.824, Applicants submit herewith a Sequence Listing satisfying the computer readable format requirements on a compact disc (CD-R) labeled "CRF." Applicants submit concurrently herewith a Statement Under 37 C.F.R. § 1.821.

Additionally, in accordance with 37 C.F.R. §§ 1.52(e), 1.821, and 1.823, Applicants submit herewith a Sequence Listing as an electronic document on two identical compact discs (CD-R). Applicants certify under 37 C.F.R. § 1.52(e)(4) that these two compact discs, labeled "Copy 1" and "Copy 2," are identical. These compact discs, formatted for an IBM-PC machine and compatible with the MS-Windows operating system, each contain the file "PTZ29C1_seqList.txt" (43,108 bytes in size, created March 6, 2002).

Respectfully submitted,

Dated: March 7, 2002


Mark J. Hyman
Attorney for Applicants

Reg. No. 46,789

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

Enclosures